Vaccine adjuvants: Current state and future trends

  title={Vaccine adjuvants: Current state and future trends},
  author={N. Petrovsky and J. Aguilar},
  journal={Immunology and Cell Biology},
  • N. Petrovsky, J. Aguilar
  • Published 2004
  • Medicine
  • Immunology and Cell Biology
  • The problem with pure recombinant or synthetic antigens used in modern day vaccines is that they are generally far less immunogenic than older style live or killed whole organism vaccines. This has created a major need for improved and more powerful adjuvants for use in these vaccines. With few exceptions, alum remains the sole adjuvant approved for human use in the majority of countries worldwide. Although alum is able to induce a good antibody (Th2) response, it has little capacity to… CONTINUE READING
    779 Citations
    Improvements in Adjuvants for New-Generation Vaccines
    • 1
    Immune modulators with defined molecular targets: cornerstone to optimize rational vaccine design.
    • 23
    • PDF
    Carbohydrate-based immune adjuvants
    • 101
    Polysaccharides: Candidates of promising vaccine adjuvants.
    • 55
    • PDF
    New Generation Vaccines : Need for Safe and Improved Adjuvants
    • 2
    • Highly Influenced
    • PDF
    Trends in Adjuvant and Vaccine Delivery Systems
    • Highly Influenced
    Vaccine adjuvants - Current status and prospects on controlled release adjuvancity.
    • 72
    Comparative Safety of Vaccine Adjuvants: A Summary of Current Evidence and Future Needs
    • 106
    Peptide Vaccine: Progress and Challenges
    • 267
    • PDF


    Inulin‐derived adjuvants efficiently promote both Th1 and Th2 immune responses
    • 101
    Adjuvants and delivery systems for viral vaccines--mechanisms and potential.
    • 33
    Future prospects for vaccine adjuvants.
    • 61
    Adjuvants in perspective.
    • F. Vogel
    • Medicine
    • Developments in biological standardization
    • 1998
    • 55
    Synthetic immunomodulators and synthetic vaccines.
    • C. Leclerc, F. Vogel
    • Biology, Medicine
    • Critical reviews in therapeutic drug carrier systems
    • 1986
    • 29
    The iscom structure as an immune-enhancing moiety: experience with viral systems.
    • 78
    • PDF
    Immunological Adjuvants and Vaccines
    • 75
    • PDF
    Adjuvant influenza vaccines.
    • 58